{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:17:37Z","timestamp":1769818657273,"version":"3.49.0"},"reference-count":34,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T00:00:00Z","timestamp":1595462400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDB\/04378\/2020"],"award-info":[{"award-number":["UIDB\/04378\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Our group recently developed a urinary 6-biomarker panel for the diagnosis of prostate cancer (PCa) which has a higher level of accuracy compared to the serum prostate specific antigen (PSA) test. Herein, urine from an independent cohort of PCa patients and cancer-free controls was analyzed to further validate the discriminative power of that panel. Additionally, urine from patients diagnosed with bladder cancer (BC) and renal cancer (RC) were included to evaluate the site-specificity of the panel. Results confirmed the ability of the 6-biomarker panel to discriminate PCa patients from controls, but not from other urological cancers. To overcome this limitation, an untargeted approach was performed to unveil discriminant metabolites among the three cancer types. A 10-biomarker panel comprising the original panel plus four new metabolites was established to discriminate PCa from controls, BC, and RC, with 76% sensitivity, 90% specificity, and 92% accuracy. This improved panel also disclosed better accuracy than serum PSA test and provides the basis for a new non-invasive early detection tool for PCa.<\/jats:p>","DOI":"10.3390\/cancers12082017","type":"journal-article","created":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T11:26:01Z","timestamp":1595503561000},"page":"2017","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["A Panel of Urinary Volatile Biomarkers for Differential Diagnosis of Prostate Cancer from Other Urological Cancers"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1439-770X","authenticated-orcid":false,"given":"Ana Rita","family":"Lima","sequence":"first","affiliation":[{"name":"UCIBIO\/REQUIMTE, Department of Biological Sciences, Laboratory of Toxicology, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9719-8364","authenticated-orcid":false,"given":"Joana","family":"Pinto","sequence":"additional","affiliation":[{"name":"UCIBIO\/REQUIMTE, Department of Biological Sciences, Laboratory of Toxicology, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal"}]},{"given":"Carina","family":"Carvalho-Maia","sequence":"additional","affiliation":[{"name":"Cancer Biology &amp; Epigenetics Group, Research Center (CI-IPOP), Porto Comprehensive Cancer Center (P.CCC), Portuguese Oncology Institute of Porto (IPO Porto), 4200-072 Porto, Portugal"},{"name":"Department of Pathology, Portuguese Oncology Institute of Porto (IPO Porto), P.CCC Porto Comprehensive Cancer Center, 4200-072 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4186-5345","authenticated-orcid":false,"given":"Carmen","family":"Jer\u00f3nimo","sequence":"additional","affiliation":[{"name":"Cancer Biology &amp; Epigenetics Group, Research Center (CI-IPOP), Porto Comprehensive Cancer Center (P.CCC), Portuguese Oncology Institute of Porto (IPO Porto), 4200-072 Porto, Portugal"},{"name":"Department of Pathology, Portuguese Oncology Institute of Porto (IPO Porto), P.CCC Porto Comprehensive Cancer Center, 4200-072 Porto, Portugal"},{"name":"Department of Pathology and Molecular Immunology, Biomedical Sciences Institute (ICBAS), University of Porto, Rua Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3171-4666","authenticated-orcid":false,"given":"Rui","family":"Henrique","sequence":"additional","affiliation":[{"name":"Cancer Biology &amp; Epigenetics Group, Research Center (CI-IPOP), Porto Comprehensive Cancer Center (P.CCC), Portuguese Oncology Institute of Porto (IPO Porto), 4200-072 Porto, Portugal"},{"name":"Department of Pathology, Portuguese Oncology Institute of Porto (IPO Porto), P.CCC Porto Comprehensive Cancer Center, 4200-072 Porto, Portugal"},{"name":"Department of Pathology and Molecular Immunology, Biomedical Sciences Institute (ICBAS), University of Porto, Rua Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal"}]},{"given":"Maria de Lourdes","family":"Bastos","sequence":"additional","affiliation":[{"name":"UCIBIO\/REQUIMTE, Department of Biological Sciences, Laboratory of Toxicology, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9884-4751","authenticated-orcid":false,"given":"M\u00e1rcia","family":"Carvalho","sequence":"additional","affiliation":[{"name":"UCIBIO\/REQUIMTE, Department of Biological Sciences, Laboratory of Toxicology, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal"},{"name":"Fernando Pessoa Energy, Environment and Health Research Unit (FP-ENAS), Faculty of Health Sciences, University Fernando Pessoa, 4249-004 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7395-5700","authenticated-orcid":false,"given":"Paula","family":"Guedes de Pinho","sequence":"additional","affiliation":[{"name":"UCIBIO\/REQUIMTE, Department of Biological Sciences, Laboratory of Toxicology, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2020,7,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Bax, C., Taverna, G., Eusebio, L., Sironi, S., Grizzi, F., Guazzoni, G., and Capelli, L. (2018). Innovative Diagnostic Methods for Early Prostate Cancer Detection through Urine Analysis: A Review. Cancers, 10.","DOI":"10.3390\/cancers10040123"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1038\/modpathol.2017.167","article-title":"Prostate cancer reporting and staging: Needle biopsy and radical prostatectomy specimens","volume":"31","author":"Grignon","year":"2018","journal-title":"Mod. Pathol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.eururo.2013.12.062","article-title":"Overdiagnosis and overtreatment of prostate cancer","volume":"65","author":"Loeb","year":"2014","journal-title":"Eur. Urol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s11934-018-0828-6","article-title":"Improving the Specificity of PSA Screening with Serum and Urine Markers","volume":"19","author":"Kearns","year":"2018","journal-title":"Curr. Urol. Rep."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3322\/caac.20066","article-title":"American Cancer Society guideline for the early detection of prostate cancer: Update 2010","volume":"60","author":"Wolf","year":"2010","journal-title":"CA Cancer J. Clin."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1093\/annonc\/mdu525","article-title":"Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis","volume":"26","author":"Louie","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_8","first-page":"83","article-title":"Emerging biomarkers in the diagnosis of prostate cancer","volume":"11","author":"Filella","year":"2018","journal-title":"Pharmgenom. Personal. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"25776","DOI":"10.1038\/srep25776","article-title":"Evaluation of prostate cancer antigen 3 for detecting prostate cancer: A systematic review and meta-analysis","volume":"6","author":"Cui","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1515\/cclm-2012-0410","article-title":"Evaluation of [-2] proPSA and Prostate Health Index (phi) for the detection of prostate cancer: A systematic review and meta-analysis","volume":"51","author":"Filella","year":"2013","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cmet.2015.12.006","article-title":"The Emerging Hallmarks of Cancer Metabolism","volume":"23","author":"Pavlova","year":"2016","journal-title":"Cell Metab."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/nature07762","article-title":"Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression","volume":"457","author":"Sreekumar","year":"2009","journal-title":"Nature"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1158\/1055-9965.EPI-15-1223","article-title":"Metabolomic Biomarkers of Prostate Cancer: Prediction, Diagnosis, Progression, Prognosis, and Recurrence","volume":"25","author":"Kelly","year":"2016","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Khalid, T., Aggio, R., White, P., De Lacy Costello, B., Persad, R., Al-Kateb, H., Jones, P., Probert, C.S., and Ratcliffe, N. (2015). Urinary Volatile Organic Compounds for the Detection of Prostate Cancer. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0143283"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Kdadra, M., Hockner, S., Leung, H., Kremer, W., and Schiffer, E. (2019). Metabolomics Biomarkers of Prostate Cancer: A Systematic Review. Diagnostics, 9.","DOI":"10.3390\/diagnostics9010021"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Capelli, L., Taverna, G., Bellini, A., Eusebio, L., Buffi, N., Lazzeri, M., Guazzoni, G., Bozzini, G., Seveso, M., and Mandressi, A. (2016). Application and Uses of Electronic Noses for Clinical Diagnosis on Urine Samples: A Review. Sensors, 16.","DOI":"10.3390\/s16101708"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/s41416-019-0585-4","article-title":"Identification of a biomarker panel for improvement of prostate cancer diagnosis by volatile metabolic profiling of urine","volume":"121","author":"Lima","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.semcancer.2017.05.010","article-title":"Methylglyoxal-derived stress: An emerging biological factor involved in the onset and progression of cancer","volume":"49","author":"Bellahcene","year":"2018","journal-title":"Semin. Cancer Biol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Antognelli, C., and Talesa, V.N. (2018). Glyoxalases in Urological Malignancies. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19020415"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1039\/C6AY00400H","article-title":"Evaluation of gas chromatography mass spectrometry and pattern recognition for the identification of bladder cancer from urine headspace","volume":"8","author":"Cauchi","year":"2016","journal-title":"Anal. Methods"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"13113","DOI":"10.1038\/s41598-018-31380-y","article-title":"Exploring the potential of NTME\/GC-MS, in the establishment of urinary volatomic profiles. Lung cancer patients as case study","volume":"8","author":"Pereira","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s40463-018-0288-5","article-title":"The volatilome\u2014Investigation of volatile organic metabolites (VOM) as potential tumor markers in patients with head and neck squamous cell carcinoma (HNSCC)","volume":"47","author":"Opitz","year":"2018","journal-title":"J. Otolaryngol. Head Neck Surg."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1038\/bjc.2011.437","article-title":"Investigation of urinary volatile organic metabolites as potential cancer biomarkers by solid-phase microextraction in combination with gas chromatography-mass spectrometry","volume":"105","author":"Silva","year":"2011","journal-title":"Br. J. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1111\/jcmm.13132","article-title":"GC-MS metabolomics-based approach for the identification of a potential VOC-biomarker panel in the urine of renal cell carcinoma patients","volume":"21","author":"Monteiro","year":"2017","journal-title":"J. Cell Mol. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"5239","DOI":"10.1007\/s00216-016-9618-5","article-title":"Headspace-programmed temperature vaporization-mass spectrometry for the rapid determination of possible volatile biomarkers of lung cancer in urine","volume":"408","author":"Ramos","year":"2016","journal-title":"Anal. Bioanal. Chem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1248\/bpb.35.639","article-title":"Metabolomics study on the biochemical profiles of odor elements in urine of human with bladder cancer","volume":"35","author":"Jobu","year":"2012","journal-title":"Biol. Pharm. Bull."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1039\/C3CS60329F","article-title":"Assessment, origin, and implementation of breath volatile cancer markers","volume":"43","author":"Haick","year":"2014","journal-title":"Chem. Soc. Rev."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.2174\/0929867323666160510122913","article-title":"A Compendium of Volatile Organic Compounds (VOCs) Released By Human Cell Lines","volume":"23","author":"Filipiak","year":"2016","journal-title":"Curr. Med. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"5949","DOI":"10.1021\/cr300174a","article-title":"Volatile organic compounds of lung cancer and possible biochemical pathways","volume":"112","author":"Hakim","year":"2012","journal-title":"Chem. Rev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.4155\/bio.12.92","article-title":"Validation study of urinary metabolites as potential biomarkers for prostate cancer detection","volume":"4","author":"Gamagedara","year":"2012","journal-title":"Bioanalysis"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Pluskal, T., Castillo, S., Villar-Briones, A., and Oresic, M. (2010). MZmine 2: Modular framework for processing, visualizing, and analyzing mass spectrometry-based molecular profile data. BMC Bioinform., 11.","DOI":"10.1186\/1471-2105-11-395"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/978-1-4939-1258-2_22","article-title":"Statistical analysis and modeling of mass spectrometry-based metabolomics data","volume":"1198","author":"Xi","year":"2014","journal-title":"Methods Mol. Biol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"W486","DOI":"10.1093\/nar\/gky310","article-title":"MetaboAnalyst 4.0: Towards more transparent and integrative metabolomics analysis","volume":"46","author":"Chong","year":"2018","journal-title":"Nucleic Acids Res."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/8\/2017\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:51:10Z","timestamp":1760176270000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/8\/2017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,23]]},"references-count":34,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,8]]}},"alternative-id":["cancers12082017"],"URL":"https:\/\/doi.org\/10.3390\/cancers12082017","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,23]]}}}